Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ICML 2017 | A novel WINDOW of opportunity for young mantle cell lymphoma patients

Michael Wang • 14 Jun 2017

ICML 2017

B-Cell Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Rituximab

Michael Wang, MD from the MD Anderson Cancer Center, Houston, TX discusses the results from the successful WINDOW study (NCT02427620), presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Prof. Wang explains the study design, which saw young, newly diagnosed mantle cell lymphoma patients receive a combination of ibrutinib and rituximab followed by reduced chemo-immunotherapy. This combination of targeted therapy achieved a response in 100% of patients and complete remission in 90%. By reducing the need for chemotherapy, treatment associated toxicities can be decreased thus giving this subset of patients a better quality of life.

SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCL

Michael Wang • 11 Dec 2023

Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors

Michael Wang • 6 Sep 2023

BRUIN study cohort update: pirtobrutinib for patients with MCL

Michael Wang • 6 Sep 2023

Lisocabtagene maraleucel for R/R MCL: TRANSCEND-NHL-001 update

Michael Wang • 6 Sep 2023

Related Videos

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024

Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing

Gloria Iacoboni • 15 Apr 2024

Using lineage tracing to define responding CAR T-cells in patients with LBCL

Zinaida Good • 9 Apr 2024